¼¼°èÀÇ °³ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå
Canine influenza Vaccines
»óǰÄÚµå : 1731975
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 371 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,118,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,355,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °³ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº 2030³â±îÁö 23¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 18¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ °³ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 23¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÀçÁ¶ÇÕ ¹é½ÅÀº CAGR 4.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÒȰȭ ¹é½Å ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 7,730¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °³ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº 2024³â¿¡´Â 4¾ï 7,730¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 4¾ï 6,740¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.0%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.7%¿Í 3.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °³ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°³ ÀÎÇ÷翣ÀÚ ¹é½ÅÀº ¿Ö ¿¹¹æ ¼öÀÇÇÐÀÇ Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í Àִ°¡?

°³ ÀÎÇ÷翣ÀÚ ¹é½ÅÀº ƯÈ÷ °³Áý, º¸È£¼Ò, º¸È£¼Ò, ±â¼÷»ç, µ¿¹°º´¿ø¿¡¼­ °³µé »çÀÌ¿¡¼­ Àü¿°¼ºÀÌ ³ôÀº È£Èí±â ÁúȯÀÇ È®»êÀ» ¾ïÁ¦ÇÏ´Â µ¥ ÇʼöÀûÀÎ Åø·Î °¢±¤À» ¹Þ°í ÀÖ½À´Ï´Ù. ÁÖ·Î H3N8 ¹× H3N2 ¹ÙÀÌ·¯½º ±ÕÁÖ¿¡ ÀÇÇØ ¹ß»ýÇϴ°³ ÀÎÇ÷翣ÀÚ´Â ±Þ¼º È£Èí±â ÁúȯÀÇ ¹ß»ý°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, ¹Ý·Áµ¿¹°ÀÇ °Ç°­°ú Áö¿ª µ¿¹° °ü¸®¿¡ ½É°¢ÇÑ À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ÀÚ¿¬ ¸é¿ªÀÌ ¾ø°í, ¹ÙÀÌ·¯½º´Â ¿¡¾î·ÎÁ¹È­µÈ ¹°¹æ¿ïÀ̳ª ¿À¿°µÈ Ç¥¸éÀ» ÅëÇØ ºü¸£°Ô ÀüÆÄµÇ¹Ç·Î ¹é½Å Á¢Á¾Àº ¿©ÀüÈ÷ °¡Àå È¿°úÀûÀÎ ¿¹¹æ ¹× Áý´Ü ¼öÁØÀÇ Áúº´ °ü¸® ÇüÅÂÀÔ´Ï´Ù.

¼¼°è¿¡¼­ ¹Ý·Áµ¿¹° »çÀ°ÀÌ Áõ°¡Çϰí, °¡Á¤, ¹Ì¿ë½Ç, Ź¾Æ¼Ò, ¾î¸°ÀÌÁý µî ¹Ý·Áµ¿¹°ÀÇ À̵¿ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼öÀÇ»çµéÀº Á¤±âÀûÀÎ ¹é½Å Á¢Á¾À» ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. °³ ÀÎÇ÷翣ÀÚ´Â ÇöÀç »ç¶÷¿¡°Ô °¨¿°µÇÁö ¾ÊÁö¸¸, Àμö°øÅëÀü¿°º´ÀÇ À§Çè¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÌ Ã¥ÀÓ°¨ ÀÖ´Â ¾Ö¿Ïµ¿¹° ÄɾîÀÇ ÀÏȯÀ¸·Î Á¾ÇÕÀûÀÎ ¿¹¹æÁ¢Á¾ Àü·«À» äÅÃÇÏ´Â µ¥ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

±ÕÁÖ Æ¯ÀÌÀû Á¦Á¦¿Í È¥ÇÕ¹é½ÅÀº ¾î¶»°Ô Á¦Ç°ÀÇ º¸±Þ°ú ¼öÀÇ»çÀÇ ¼øÀÀµµ¸¦ ³ôÀ̰í Àִ°¡?

Á¦Á¶¾÷ü´Â 1°¡ ¹é½Å(H3N8 ¶Ç´Â H3N2)°ú 2°¡ ¹é½ÅÀ» ¸ðµÎ Á¦°øÇϰí ÀÖÀ¸¸ç, À¯ÅëµÇ´Â ±ÕÁÖ¿¡ ´ëÇØ º¸´Ù ±¤¹üÀ§ÇÑ ¹æ¾î·ÂÀ» Á¦°øÇÕ´Ï´Ù. µÎ °¡Áö ¹ÙÀÌ·¯½º À¯ÇüÀÌ °øÁ¸Çϰí ÀÌÁß ±ÕÁÖ ¹ß»ý °¡´É¼ºÀÌ ÀÖÀ¸¹Ç·Î ¸¹Àº ½ÃÀå¿¡¼­ 2°¡ Á¦Á¦°¡ Ç¥ÁØÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¹é½ÅÀº ÀϹÝÀûÀ¸·Î 2ȸ Á¢Á¾ ÈÄ ¿¬ 1ȸ Ãß°¡ Á¢Á¾À» ÅëÇØ °íÀ§Ç豺 ¹Ý·Á°ß¿¡°Ô Àϳ⠳»³» È®½ÇÇÑ ¿¹¹æ È¿°ú¸¦ Á¦°øÇÕ´Ï´Ù.

¶ÇÇѰ³ ÀÎÇ÷翣ÀÚ ¿¹¹æÀ» º¼µ¥ÅÚ¶ó, ÆÄ¶óÀÎÇ÷翣ÀÚ, µð½ºÅÛÆÛ¿Í °°Àº ´Ù¸¥ ÇÙ½É Ç׿ø°ú °áÇÕµÈ ´Ù°¡ È¥ÇÕ ¹é½Å¿¡°³ ÀÎÇ÷翣ÀÚ ¿¹¹æÀ» ÅëÇÕÇÏ¿© º¸È£ÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÌ°í ¼öÀÇÇÐ Áø·áÀÇ ¹°·ù À庮À» ³·Ãß°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÇÕÁ¦Á¦´Â Á¾ÇÕÀûÀΠȣÈí±â º¸È£ ±â´ÉÀ» Á¦°øÇϸ鼭 Åõ¿©¸¦ °£¼ÒÈ­ÇÏ¿© º¸È£ ÀÇ·á ¹× Á¤±âÀûÀÎ À£´Ï½º ÇÁ·ÎÅäÄÝ¿¡¼­ ƯÈ÷ ¸Å·ÂÀûÀÔ´Ï´Ù.

°³ ÀÎÇ÷翣ÀÚ ¹é½Å ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â Áö¿ª°ú ½ÃÀå È®´ë¸¦ °ßÀÎÇϰí ÀÖ´Â ¹Ý·Áµ¿¹° »çÀ° µ¿ÇâÀº?

ºÏ¹Ì´Â°³ ÀÎÇ÷翣ÀÚ ¹é½ÅÀÇ ÃÖ´ë ½ÃÀåÀ̸ç, ±× ¿øµ¿·ÂÀº źźÇÑ ¾Ö¿Ïµ¿¹° Äɾî ÀÎÇÁ¶ó, ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ³ôÀº ÀνÄ, ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ ±âÁØÀ» Çü¼ºÇÑ °ú°Å Áö¿ªÀû À¯ÇàÀÌ ±× ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº Á¶Á÷È­µÈ ¹Ý·Áµ¿¹° ¼­ºñ½ºÀÇ º¸±Þ°ú ÁÖ ¶Ç´Â ½Ã¼³ Â÷¿øÀÇ ¹é½Å Àǹ«È­·Î ¹é½Å º¸±ÞÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º¿¡¼­´Â ¹Ý·Áµ¿¹° ¿©Çà °ü·Ã ±ÔÁ¤°ú »çÀ°Àå ±âÁØ µîÀ¸·Î ÀÎÇØ ¼±Á¦Àû ¹é½Å Á¢Á¾À» Àå·ÁÇϰí ÀÖ½À´Ï´Ù.

Áß±¹, ÀϺ», Çѱ¹ µîÀÇ ±¹°¡¿¡¼­ µµ½ÃÈ­, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ¹Ý·Áµ¿¹° »çÀ°ÀÇ È®´ë°¡ ¹Ý·Áµ¿¹° ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖÀ¸¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº °¡¼ÓÈ­µÈ ¼ºÀåÀ» ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â µ¿¹°º´¿ø¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í, À¯·´°ú ¹Ì±¹ÀÇ ¿¹¹æÀÇÇÐÀÌ ¿µÇâ·ÂÀ» È®´ëÇÔ¿¡ µû¶ó ¹Ý·Áµ¿¹° »çÀ°ÀÌ º¸´Ù ü°èÈ­µÇ¾î °¡°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° º¸Çè°ú À£´Ï½º Ç÷£ÀÇ ¿ªÇÒ Áõ°¡µµ µ¶°¨À» Æ÷ÇÔÇÑ Á¤±âÀûÀÎ ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ µ¿±â¸¦ ºÎ¿©Çϰí ÀÖ½À´Ï´Ù.

°³ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ¼¼°è ¼ºÀå µ¿·ÂÀº ¹«¾ùÀΰ¡?

¼¼°è°³ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº Áúº´ °¨½Ã °­È­, ¼öÀÇ»çÀÇ ¿¹¹æÀÇÇÐ µµÀÔ Áõ°¡, ¹Ý·Áµ¿¹°ÀÇ °Ç°­¿¡ ´ëÇÑ °æÁ¦Àû °¡Ä¡ Áõ°¡·Î ÀÎÇØ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Áúº´ ¹ß»ý, ¾ð·Ð º¸µµ, Àü¹®°¡ ÇùȸÀÇ °¡À̵å¶óÀο¡ µû¶ó ´ëÁß°ú ¼öÀÇÇаè´Â ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¿¹°º´¿øÀÇ ÅëÇÕ, ±â¾÷ ¼öÀÇ»ç ³×Æ®¿öÅ©ÀÇ È®´ë, ¹Ý·Áµ¿¹° µ¹º½ ¼¾ÅÍ ¹× µ¥ÀÌÄÉ¾î ¼­ºñ½ºÀÇ È®´ë·Î ÀÎÇØ ¹é½Å Á¢Á¾ÀÌ ¾÷¹« ÇÁ·ÎÅäÄÝÀÇ ÀϺηΠÁ¦µµÈ­µÇ°í ÀÖ½À´Ï´Ù.

ÄݵåüÀÎ ¹°·ù ¹× ¼¼°è À¯Åë¿¡ ´ëÇÑ ÅõÀÚ¿Í ÇÔ²² ¹é½Å ±â¼ú, ±ÕÁÖ Å¸°ÙÆÃ, Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ ¹ßÀüÀÌ ½ÃÀåÀÇ È®À强À» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° °Ç°­ÀÌ Á¡Á¡ ´õ ÀÇ·áÈ­µÇ°í ¿¹¹æ¿¡ ÁßÁ¡À» µÎ°Ô µÇ¸é¼­ °áÁ¤ÀûÀÎ Àǹ®ÀÌ Á¦±âµÇ°í ÀÖ½À´Ï´Ù. °³ ÀÎÇ÷翣ÀÚ ¹é½Å Á¦Á¶¾÷üµéÀÌ Áö¿ªÀû À§Çè ÇÁ·ÎÆÄÀÏ¿¡ ´ëÀÀÇϰí, Á¡Á¡ ´õ À̵¿ÇÏ°í µµ½ÃÈ­µÇ´Â ¼¼°è ¹Ý·Áµ¿¹° Àα¸¿¡ ´ëÇÑ ÀϰüµÈ ¿¹¹æÀ» º¸ÀåÇϸ鼭 ÀÎÁöµµ¸¦ ³ôÀ̰í, Á¢±Ù¼ºÀ» ³ôÀ̸ç, ´Ù¾çÇÑ Á¦Ç° Çõ½ÅÀ» È®´ëÇÒ ¼ö Àִ°¡?

ºÎ¹®

¹é½Å À¯Çü(ÀçÁ¶ÇÕ ¹é½Å, ºÒȰȭ ¹é½Å, ±âŸ ¹é½Å À¯Çü), ¹ÙÀÌ·¯½º À¯Çü(H3N8 ¹ÙÀÌ·¯½º, H3N2 ¹ÙÀÌ·¯½º), ÆÇ¸Åä³Î(°ø°ø, ¹Î°£)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 44»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>Áß±¹ <>¸ß½ÃÄÚ <>ij³ª´Ù <>EU <>ÀϺ» <>Àεµ <>±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Canine influenza Vaccines Market to Reach US$2.3 Billion by 2030

The global market for Canine Influenza Vaccines estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$477.3 Million While China is Forecast to Grow at 8.0% CAGR

The Canine influenza Vaccines market in the U.S. is estimated at US$477.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$467.4 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Canine Influenza Vaccines Market - Key Trends & Drivers Summarized

Why Are Canine Influenza Vaccines Becoming a Critical Component of Preventive Veterinary Care?

Canine influenza vaccines are gaining prominence as essential tools in controlling the spread of highly contagious respiratory diseases among dogs-particularly in kennels, shelters, boarding facilities, and veterinary clinics. Canine influenza, caused primarily by the H3N8 and H3N2 virus strains, is associated with outbreaks of acute respiratory illness and presents a significant threat to pet health and community animal management. With no lasting natural immunity and rapid viral transmission through aerosolized droplets or contaminated surfaces, vaccination remains the most effective form of prevention and population-level disease control.

As pet ownership increases globally and mobility between households, grooming centers, and daycare facilities rises, veterinarians are increasingly recommending routine vaccination-especially for dogs in high-density environments or with frequent social exposure. Rising awareness of zoonotic risks, even though canine influenza does not currently transmit to humans, is also influencing owners to adopt comprehensive immunization strategies as part of responsible pet care.

How Are Strain-Specific Formulations and Combination Vaccines Enhancing Product Adoption and Veterinary Compliance?

Manufacturers are offering both monovalent (H3N8 or H3N2) and bivalent vaccines that provide broader protection against circulating strains. Bivalent formulations are becoming the standard in many markets due to the co-circulation of both virus types and the potential for dual-strain outbreaks. These vaccines are typically administered in a two-dose series followed by annual boosters, ensuring year-round protection in high-risk dogs.

In addition, the integration of canine influenza protection into multivalent combination vaccines-bundled with other core antigens such as bordetella, parainfluenza, and distemper-is improving owner compliance and reducing logistical barriers in veterinary practice. These combination formulations are particularly attractive in shelter medicine and routine wellness protocols, streamlining administration while delivering comprehensive respiratory protection.

Where Is Demand for Canine Influenza Vaccines Rising and Which Pet Ownership Trends Are Driving Market Expansion?

North America is the largest market for canine influenza vaccines, driven by robust pet care infrastructure, high levels of vaccination awareness, and past regional outbreaks that have shaped preventive care standards. The United States, in particular, leads in vaccine adoption due to the prevalence of organized pet services and state or facility-level vaccine mandates. Europe follows with steady growth, especially in the U.K., Germany, and France, where pet travel regulations and kennel standards encourage preemptive vaccination.

Asia-Pacific is witnessing accelerated growth, with urbanization, rising disposable income, and expanding pet ownership in countries such as China, Japan, and South Korea driving demand for companion animal vaccines. Pet adoption in these regions is becoming more structured, with greater access to veterinary care and growing influence of Western preventive care practices. The increasing role of pet insurance and wellness plans is also incentivizing routine immunization, including influenza coverage.

What Is Fueling the Global Growth of the Canine Influenza Vaccines Market?

The global canine influenza vaccines market is expanding due to heightened disease surveillance, increasing veterinary preventive care adoption, and the growing economic value placed on companion animal health. Outbreak events, media coverage, and professional association guidelines have strengthened public and veterinary sector emphasis on immunization. Additionally, the consolidation of veterinary practices, growth of corporate vet networks, and expansion of pet boarding and daycare services are institutionalizing vaccine compliance as part of operational protocols.

Advances in vaccine technology, strain targeting, and delivery mechanisms-alongside investments in cold chain logistics and global distribution-are supporting market scalability. As companion animal health becomes more medicalized and prevention-focused, a defining question emerges: Can canine influenza vaccine manufacturers scale awareness, access, and multivalent product innovation-while addressing regional risk profiles and ensuring consistent protection in an increasingly mobile and urbanized global pet population?

SCOPE OF STUDY:

The report analyzes the Canine influenza Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Recombinant Vaccines, Inactivated Vaccines, Other Vaccine Types); Virus Type (H3N8 virus, H3N2 virus); Distribution Channel (Public, Private)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â